Divergent effects of glucocorticoids on cortical and trabecular compartment BMD in childhood nephrotic syndrome

Journal of Bone and Mineral Research

Volumn 24, Issue 3, 2009, Pages 503-513

  Wetzsteon, Rachel J ^a   Shults, Justine ^b   Zemel, Babette S ^a   Gupta, Pooja U ^c   Burnham, Jon M ^a   Herskovitz, Rita M ^a   Howard, Krista M ^a   Leonard, Mary B ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BMD; Children; Glucocorticoids; Nephrotic syndrome; PQCT

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEOXYPYRIDINOLINE; FUROSEMIDE; GLUCOCORTICOID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; VITAMIN D;

ADOLESCENT; ADULT; ARTICLE; BONE DENSITY; BONE TURNOVER; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICAL BONE; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE; NEPHROTIC SYNDROME; OSSIFICATION; OSTEOLYSIS; OUTCOME ASSESSMENT; RACE; SCORING SYSTEM; SEX; TIBIA; TRABECULAR BONE; URINE LEVEL; VOLUMETRY;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE REMODELING; CASE-CONTROL STUDIES; CHILD; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; NEPHROTIC SYNDROME; PARATHYROID HORMONE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VITAMIN D;

EID: 61849089392     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.081101     Document Type: Article

References (58)

1. van Staa TP. Cooper C, Leufkens HG, Bishop N 200? Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res 18:913-918.
2. Foster BJ, Shulls J, Zemel BS, Leonard MB 2004 Interactions between growth and body composition in children treated with high-dose chronic glucocorticoids. Am J Clin Nutr 80:1334-1341.
3. Dalle Carbonate L, Arlot ME, Chavassieux PM, Roux JP, Portero NR, Meunier PJ 2001 Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 16:97-103.
4. Canalis E, Mazziotti G, Giustina A, Bilezikian JP 2007 Glucocorticoid-induced osteoporosis: Pathophysiology and therapy. Osteoporos Int 18:1319-1328.
5. O'Brien CA. Jia D, Plolkin LI, Bellido T, Powers CC, Stewart SA, Manolagas SC, Weinstein RS 2004 Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145:1835-1841.
6. Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia LJ, Ross FP, Teitelbaum SL 2006 Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 116:2152-2160.
7. Gilbert L, He X, Farmer P, Rubin J, Drissi H, van Wijnen AJ, Lian JB, Stein GS, Nanes MS 2002 Expression of the osteoblast differentiation factor RUNX2 (Cbfal/AML3/Pebp2al-pha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem 277:2695-2701.
8. Ahuja SS, Zhao S, Bellido T. Plotkin LI, Jimenez F. Bonewald LF 2003 CD40 ligand blocks apoptosis induced by tumor necrosis factor alpha, glucocorticoids, and etoposide in osteoblasts and the osteocyte-like cell line murine long bone osteocyte-Y4. Endocrinology 144:1761-1769.
9. Kudo O. Fujikawa Y, Itonaga I, Sabokbar A, Torisu T, Athanasou NA 2002 Proinflammatory cytokine (TNFalpha/IL-lalpha) induction of human osteoclast formation. J Pathol 198:220-227.
10. Kwan Tat S, Padrines M, Theoleyre S, Heymann D. Fortun Y 2004 IL-6, RANKL, TNF-alpha/IL-1: Interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 15:49-60.
11. Brodehl J 1991 The treatment of minimal change nephrotic syndrome: Lessons learned from multicentre co-operative studies. Eur J Pediatr 150:380-387.
12. van Staa TP, Leufkens HG, Cooper C 2002 The epidemiology of corticosteroid-induced osteoporosis: A meta- analysis. Osteoporos Int 13:777-787.
13. Daniel V, Trautmann Y, Konrad M, Nayir A, Scharer K 1997 T-lymphocyte populations, cytokines and other growth factors in serum and urine of children with idiopathic nephrotic syndrome. Clin Nephrol 47:289-297.
14. Leonard MB, Feldman HI. Shults J, Zemel BS, Foster BJ, Stallings VA 2004 Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. N Engl J Med 351:868-875.
15. Burnham JM, Shults J, Petit MA, Semeao E, Beck TJ, Zemel BS, Leonard MB 2007 Alterations in proximal femur geometry in children treated with glucocorticoids for Crohn disease or nephrotic syndrome: Impact of the underlying disease. J Bone Miner Res 22:551-559.
16. Augat P, Reeb H, Claes LE 1996 Prediction of fracture load at different skeletal sites by geometric properties of the cortical shell. J Bone Miner Res 11:1356-1363.
17. Liu D, Manske SL, Kontulainen SA, Tang C, Guy P, Oxland TR, McKay HA 2007 Tibial geometry is associated with failure load ex vivo: A MRI, pQCT and DXA study. Osteoporos Int 18:991-997.
18. 1981 The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 98:561-564.
19. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A 1976 A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259-263.
20. Tanner JM 1962 Growth at Adolescence, 2nd ed. Blackwell Scientific Publications, Oxford, UK.
21. Morris NM, Udry JR, 1980 Validation of a self-administered instrument to assess stage of adolescent development. J Youth Adolesc 9:271-280.
22. Ashe MC, Khan KM, Kontulainen SA, Guy P, Liu D, Beck TJ, McKay HA 2006 Accuracy of pQCT for evaluating the aged human radius: An ashing, histomorphometry and failure load investigation. Osteoporos Int 17:1241-1251.
23. Leonard MB, Shults J, Zemel BS 2006 DXA estimates of vertebral volumetric bone mineral density in children: Potential advantages of paired posteroanterior and lateral scans. J Clin Densitom 9:265-273.
24. Jergas M, Breitenseher M, Gluer CC, Yu W, Genant HK1995 Estimates of volumetric bone density from projectional measurements improve the discriminatory capability of dual X-ray absorptiometry. J Bone Miner Res 10:1101-1110.
25. Jergas M, Breitenseher M, Gluer CC, Black D, Lang P. Grampp S. Engelke K. Genant HK 1995 Which vertebrae should be assessed using lateral dual-energy X-ray absorptiometry of the lumbar spine. Osteoporos Int 5:196-204.
26. Hollis BW 1997 Quantitation of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D by radioimmunoassay using radioi-odinated tracers. Methods Enzymol 282:174-186.
27. Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R, Grummer-Strawn LM, Curtin LR, Roche AF, Johnson CL 2002 Centers for Disease Control and Prevention 2000 growth charts for the United States: Improvements to the 1977 National Center for Health Statistics version. Pediatrics 109:45-60.
28. Krebs NF, Jacobson MS 2003 Prevention of pediatric overweight and obesity. Pediatrics 112:424-430.
29. Cole TJ 1990 The LMS method for constructing normalized growth standards. Eur J Clin Nutr 44:45-60.
30. Cole TJ. Green PJ 2006 LMS Chartmaker Pro. Child Growth Foundation, London, UK.
31. Tuchman S, Thayu M, Shults J, Zemel BS, Burnham JM, Leonard MB 2008 Interpretation of biomarkers of bone metabolism in children: Impact of growth velocity and body size in healthv children and chronic disease. J Pediatr 153:484-490.
32. Weng FL, Shults J, Leonard MB, Stallings VA, Zemel BS 2007 Risk factors for low serum 25-hydroxyvitamin D concentrations in otherwise healthy children and adolescents. Am J Clin Nutr 86:150-158.
33. Clark A, Barratt TM 1999 Steroid-responsive nephrotic syndrome. In: Barratt TM, Avner ED, Harmon WE (eds.) Pediatric Nephrology, 4th cd. Lipppincott, Williams & Wilkins, Baltimore, MD. USA, pp. 731-748.
34. Binkley TL, Specker BL 2000 pQCT measurement of bone parameters in young children: Validation of technique. J Clin Densitom 3:9-14.
35. Hegarty J. Mughal MZ, Adams J. Webb NJ 2005 Reduced bone mineral density in adults treated with high-dose corticosteroids for childhood nephrotic syndrome. Kidney Int 68:2304-2309.
36. Petit MA, Beck TJ, Lin HM, Bentley C, Legro RS, Lloyd T 2004 Femoral bone structural geometry adapts to mechanical loading and is influenced by sex steroids: The Penn State Young Women's Health Study. Bone 35:750-759.
37. Leonard MB, Shults J, Wilson BA, Tershakovec AM, Zemel BS 2004 Obesity during childhood and adolescence augments bone mass and bone dimensions. Am J Clin Nutr 80:514-523.
38. Rauch F, Schoenau E 2001 Changes in bone density during childhood and adolescence: An approach based on bone's biological organization. J Bone Miner Res 16:597-604.
39. Dalle Carbonare L. Bertoldo F. Valenti MT, Zenari S, Zanatta M, Sella S, Giannini S, Cascio VL 2005 Histomorphometric analysis of glucocorticoid-induced osteoporosis. Micron 36:645-652.
40. Roschger P, Paschalis EP, Fratzl P, Klaushofer K 2008 Bone mineralization density distribution in health and disease. Bone 42:456-466.
41. Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K 2001 Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29:185-191.
42. Lettgen B, Jeken C, Reiners C 1994 Influence of steroid medication on bone mineral density in children with nephrotic syndrome. Pediatr Nephrol 8:667-670.
43. Broyer M, Terzi F, Lehnert A, Gagnadoux MF, Guest G, Niaudet P 1997 A controlled study of deflazacort in the treatment of idiopathic nephrotic syndrome. Pediatr Nephrol 11:418-422.
44. Tenbrock K, Kruppa S, Mokov E, Querfeld U, Michalk D, Schoenau E 2000 Analysis of muscle strength and bone structure in children with renal disease. Pediatr Nephrol 14:669-672.
45. Vedi S, Elkin SL, Compston JE 2005 A histomorphometric study of cortical bone of the iliac crest in patients treated with glucocorticoids. Calcif Tissue Int 77:79-83.
46. Lian KC, Lang TF, Keyak JH, Modin GW, Rehman Q, Do L, Lane NE 2005 Differences in hip quantitative computed tomography (QCT) measurements of bone mineral density and bone strength between glucocorticoid-treated and glucocorti-coid-naive postmenopausal women. Osteoporos Int 16:642-650.
47. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD 1998 Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102:1627-1633.
48. Schweizer R, Martin DD, Schwarze CP, Binder G, Georgiadou A, lhle J, Ranke MB 2003 Cortical bone density is normal in prepubertal children with growth hormone (GH) deficiency, but initially decreases during GH replacement due to early bone remodeling. J Clin Endocrinol Metab 88:5266-5272.
49. Davison KS, Siminoski K, Adachi JD, Hanley DA, Goltzman D, Hodsman AB, Josse R, Kaiser S, Olszynski WP, Papaioannou A, Ste-Marie LG, Kendler DL, Tenenhouse A, Brown JP 2006 Bone strength: The whole is greater than the sum of its parts. Semin Arthritis Rheum 36:22-31.
50. Currey JD, Brear K, Zioupos P 1996 The effects of ageing and changes in mineral content in degrading the toughness of human femora. J Biomech 29:257-260.
51. Boskey AL, DiCarlo E, Paschalis E, West P, Mendelsohn R 2005 Comparison of mineral quality and quantity in iliac crest biopsies from high- and low-turnover osteoporosis: An FT-IR microspectroscopic investigation. Osteoporos Int 16:2031-2038.
52. Jepsen KJ, Pennington DE, Lee YL, Warman M, Nadeau J 2001 Bone brittleness varies with genetic background in A/J and C57BL/6J inbred mice. J Bone Miner Res 16:1854-1862.
53. Tommasini SM, Nasser P, Schaffler MB, Jepsen KJ 2005 Relationship between bone morphology and bone quality in male tibias: Implications for stress fracture risk. J Bone Miner Res 20:1372-1380.
54. Dubner SE, Shults J, Leonard MB, Zemel BS, Sembhi H, Burnham JM 2008 Assessment of spine bone mineral density in juvenile idiopathic arthritis: Impact of scan projection. J Clin Densitom 11:302-308.
55. Reid IR, Evans MC, Stapleton J 1992 Lateral spine densitometry is a more sensitive indicator of glucocorticoid-induced bone loss. J Bone Miner Res 7:1221-1225.
56. Grymonprez A, Proesmans W, Van Dyck M, Jans I, Goos G, Bouillon R 1995 Vitamin D metabolites in childhood nephrotic syndrome. Pediatr Nephrol 9:278-281.
57. Canaff L, Zhou X, Hendy GN 2008 The proinflammatory cytokine, interleukin-6, up-regulates calcium-sensing receptor gene transcription via Statl/3 and Spl/3. J Biol Chem 283:13586-13600.
58. Canaff L, Hendy GN 2005 Calcium-sensing receptor gene transcription is up-regulated by the proinflammatory cytokine, interleukin-lbeta. Role of the NF-kappaB PATHWAY and kappaB elements. J Biol Chem 280:14177-14188.